Navigation Links
New Device Treats Common Heart Rhythm Disorder

It could replace anti-clotting drug warfarin for many patients, researchers say,,,,

SATURDAY, March 28 (HealthDay News) -- An implanted device may soon replace the anti-clotting drug warfarin as the first line of treatment for many people with atrial fibrillation, a new study suggests.

People with atrial fibrillation have a sixfold increased risk of stroke, the researchers noted, and typically need to take warfarin for the rest of their lives. Atrial fibrillation is a common heart rhythm problem that causes the upper chamber of the heart to beat irregularly.

"One in four people over 50 will develop atrial fibrillation," lead researcher Dr. David R. Holmes Jr., the Scripps Professor of Medicine at the Mayo Graduate School of Medicine, said during a morning teleconference at the American College of Cardiology annual meeting Saturday in Orlando, Fla.

About 3 million people in the United States have atrial fibrillation, and 16 million Americans will have the condition by 2050, Holmes said. Stroke is the most serious complication related to atrial fibrillation, he noted.

"We know that in those patients with atrial fibrillation that the clot that causes that stroke comes from a certain area of the heart called the left atrial appendage," Holmes said, explaining that the appendage is a muscular pouch connected to the left atrium. "The device isolates the left atrial appendage."

To implant the device, an interventional cardiologist uses a catheter inserted in a leg vein to guide the device into the heart; the device travels through the heart's right chamber and is deposited into the left atrium through a puncture hole between the two chambers of the heart, the researchers explained.

Current treatment with warfarin is effective in preventing strokes caused by clots associated with atrial fibrillation, but its use needs to be monitored monthly to assure patients are receiving the safest and most effective dose because it can cause serious bleeding if given in doses that are too high, Holmes noted.

In the Embolic Protection in Patients With Atrial Fibrillation (PROTECT AF) trial, researchers compared treatment with warfarin to a fabric-covered, expandable cage called the WATCHMAN. The device blocks blood clots that typically form in the heart's left atrial appendage. The 707 patients were randomly assigned to one of the two treatments.

"Efficacy was dramatically better with the device, and stopping the warfarin," Holmes said.

The researchers found that patients with the WATCHMAN had a 32 percent lower risk of stroke and cardiovascular death compared with warfarin therapy. This was especially true for hemorrhagic stroke, which causes bleeding in the brain and is usually fatal, Holmes noted.

In addition, there were fewer complications with the device, once it was implanted, compared to warfarin. Most complications with the device occurred when placing it in the heart, but these complications now occur in only 1 percent of patients, Holmes noted.

The researchers concluded that the device is an effective alternative to warfarin for preventing stroke in patients with atrial fibrillation, particularly those at the highest risk of stroke.

"A strategy like this can be used in patients with non-valvular atrial fibrillation to prevent stroke, and get them off warfarin," Holmes said.

Dr. Gregg C. Fonarow, professor of cardiology at the University of California, Los Angeles, thinks this device will benefit many patients with atrial fibrillation.

"The major risk of atrial fibrillation is blood clots forming in the heart, and then breaking loose to cause stroke. Most of these blood clots form in the appendage of the left atrium," Fonarow said.

The only effective treatment until now was lifelong use of warfarin. Researchers have been searching for alternative therapies to warfarin to protect patients with atrial fibrillation from stroke without success for decades, Fonarow noted.

"The findings from this clinical trial are very impressive," Fonarow said. "Although there were some procedure-related complications, treatment with this novel device will be very attractive and provide patients with atrial fibrillation effective, long-term protection from stroke and systemic embolization without the bleeding risks associated with warfarin."

More information

For more information on atrial fibrillation, visit the American Heart Association.

SOURCES: Gregg C. Fonarow, M.D., professor, cardiology, University of California, Los Angeles; March 28, 2009, teleconference with: David R. Holmes, Jr., M.D., Scripps Professor of Medicine, Mayo Graduate School of Medicine, Rochester, Minn.

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New BSI CE-Onsite Facilitates CE Marking Reviews for Device Manufacturers
2. Mayo study shows simple finger device may help predict future heart events, such as heart attack
3. Mayo Study Shows Simple Finger Device May Help Predict Future Heart Events, Such as Heart Attack
4. IH Systems Enters the Middle Eastern Medical Device Market
5. Chubb Named Preferred Insurance Provider for Medical Device Manufacturers
6. New Cardiovascular and Orthopaedic Content Pushes Materials for Medical Devices Database to Milestone
7. Scientists trial device to treat chemotherapy-related nausea
8. Unique nerve-stimulation device proves effective against epilepsy
9. Materials for Medical Devices Database Reaches Milestone
10. Insulin Pens and Growing Diabetic Community Increase Market for Insulin Delivery Devices in Europe, Says Frost & Sullivan
11. HemAway(R) Launches FDA-Cleared Painless Hemorrhoid Treatment Device
Post Your Comments:
Related Image:
New Device Treats Common Heart Rhythm Disorder
(Date:11/25/2015)... ... ... “While riding the bus, I saw a passenger in a wheelchair drenched from ... a convenient and comfortable way to protect them from bad weather, so I invented ... during cold or inclement weather. In doing so, it ensures that the user remains ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... An unlikely combination ... in a way for homeless people to have a more dignified and comfortable ... initiative whereby they are repurposing plastic bags into sleeping mats for the homeless. ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... focused on providing comprehensive solutions involving adult stem cell therapies to patients with ... deemed the “Regenestem” name as a Registered Trademark (RTM). , Organizations are required ...
(Date:11/24/2015)... ... 2015 , ... Genesis Chiropractic Software helps practice owners automate ... between the practice owner and the patient that automatically manages all five aspects ... Click here to learn more. , According to Dr. Brian ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , November 25, 2015 Kitov ... ) (TASE: KTOV), a biopharmaceutical company focused on the ... various clinical conditions, today announced the closing of its ... Shares ( ADSs ), each representing 20 ordinary shares ... 3,158,900 ADSs. The ADSs and warrants were issued in ...
(Date:11/25/2015)... , Nov. 25, 2015 Allergan ... pharmaceutical company, and Rugen Therapeutics, a start-up  biotechnology ... for unmet CNS disorders and funded by the ... they have entered into an exclusive collaboration to ... for Autism Spectrum Disorders (ASD) and Obsessive Compulsive ...
(Date:11/25/2015)... Israel , November 25, 2015 ... "New Investors"), pursuant to which BioLight and the New ... IOPtima Ltd. subsidiary ("IOPtima") via a private placement. The ... of its innovative IOPtimate™ system used in the treatment ... approval pathway process for the IOPtimate™ system with the ...
Breaking Medicine Technology: